DELFI Diagnostics Inc, a US-based developer of accessible blood-based tests that to enhance cancer detection, announced on Tuesday that it has selected Lahey Hospital & Medical Center (LHMC), part of Massachusetts-based Beth Israel Lahey Health (BILH), to use its FirstLook Lung cancer screening test to help improve screening rates in the greater Boston area.

Under the partnership, Lahey will incorporate DELFI's blood-based lung cancer screening test in the primary care setting on patients eligible for lung cancer screening. Studies show that lung cancer screening can reduce lung cancer death rates by 20% or more.

Peter B. Bach, DELFI's chief medical officer, said: "We are thrilled to team with Lahey Hospital & Medical Center to improve the health of the communities it serves by improving lung cancer screening rates while expanding our reach to the Northeast. Today, screening rates are paltry -- under 10% nationwide. FirstLook Lung offers providers and their patients an accessible and convenient way to improve lung cancer detection through a simple blood test."